OmicsDiscoveries

Berlin, Germany· Est. 2017

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

OmicsDiscoveries is a Berlin-based biotech firm operating at the intersection of proteomics, genomics, and machine learning. The company has developed the RNAvision platform, a software-as-a-service solution that integrates RNA-seq data with clinical information to prioritize genetic variants and improve diagnostic yield for rare diseases. Its tools, including OUTRIDER, FRASER, and DROP, are research-validated and aim to convert variants of uncertain significance (VUS) into actionable findings. The company targets the research and molecular diagnostics markets, offering a bridge between advanced genomic research and clinical application.

Rare Diseases

Technology Platform

RNAvision platform, integrating the DROP workflow with its component tools OUTRIDER (aberrant expression detection) and FRASER (aberrant splicing detection). It uses AI/ML to prioritize genetic variants by combining RNA-seq data with DNA and clinical information.

Opportunities

The growing adoption of RNA sequencing as a complementary tool to DNA analysis for rare disease diagnosis presents a significant market opportunity.

Large-scale national and institutional genome projects are generating vast amounts of data that require sophisticated interpretation tools like RNAvision.

Expansion into clinical diagnostics and partnerships with pharmaceutical companies for target discovery offer additional growth avenues.

Risk Factors

Key risks include slower-than-expected clinical adoption of RNA-seq in standard diagnostic workflows, competition from larger, established bioinformatics and genomics companies, and the significant regulatory hurdles associated with transitioning from a research tool to a clinically validated diagnostic platform.

The company's reliance on a niche (rare disease RNA-seq) also presents market concentration risk.

Competitive Landscape

OmicsDiscoveries competes in the bioinformatics and genomic data interpretation market. Direct competitors include other specialized RNA-seq analysis software providers and consultancies. Broader competition comes from large genomic platform companies (e.g., Illumina, Sophia Genetics, Qiagen) that offer integrated data analysis suites. The company's differentiation lies in its exclusive focus on RNA-seq for rare diseases, its research-validated, peer-reviewed algorithms, and its integrative prioritization approach.